Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 81

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 81
---
 expectations
of investors and other key stakeholders or our initiatives are not executed as planned, our reputation and financial results could be
materially and adversely affected.

Additionally, the emphasis
on ESG matters, including diversity initiatives, has resulted and may result in the adoption of new laws and regulations, including new
reporting requirements in various jurisdictions. Our failure to comply with any applicable rules or regulations could lead to fines and
penalties, including risk of litigation and investigation, and adversely impact our reputation, customer attraction and retention, access
to capital and employee retention. Such ESG matters may also impact our suppliers, customers and business partners, which may augment
or cause additional impacts on our business, financial condition or results of operations.

We may explore strategic collaborations
that may never materialize or we may be required to relinquish important rights to and control over the development and commercialization
of our product candidates to any future collaborators.

Our business strategy includes
broadening our platform by potentially exploring strategic partnerships that maximize the potential of our Alpha DaRT technology. As a
result, we intend to periodically explore a variety of possible strategic partnerships in an effort to gain access to additional resources,
indications or combination therapy opportunities, or development of supportive or complementary products. These strategic partnerships
may include partnerships with large strategic partners. At the current time however, we cannot predict what form such a strategic collaboration
might take. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations
can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable
terms, if at all. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect
to relinquish some or all of the control over the future success of our Alpha DaRT technology to the third party. We are unable to predict
when, if ever, we will enter into any strategic partnerships because of the numerous risks and uncertainties associated with establishing
them, including:

  expenditure of substantial operational, financial and management resources;  

  dilutive issuances of our securities;  

  substantial actual or contingent liabilities; and  

  termination or expiration of the arrangement, which would delay the development and may increase the cost of developing our Alpha DaRT technology.  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Strategic partners may also
delay clinical trials, experience financial difficulties, provide insufficient funding, terminate